Hunan Nucien Pharmaceutical Co (SHSE:688189) ROCE %: -8.52% (As of Mar. 2026)


SHSE:688189 Hunan Nucien Pharmaceutical Co Ltd SHSE:688189
52 GF Score
Price ¥5.98
GF Value ¥2.38
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Hunan Nucien Pharmaceutical Co ROCE %?

Hunan Nucien Pharmaceutical Co SHSE:688189 -1.32% 52 ROCE % is -8.52% as of Mar. 2026. GuruFocus rates SHSE:688189 with a GF Score™ of 52/100 and a GF Value™ of ¥2.38 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hunan Nucien Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was -8.52%.

Hunan Nucien Pharmaceutical Co  (SHSE:688189) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hunan Nucien Pharmaceutical Co ROCE % Related Terms

Hunan Nucien Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Hunan Nucien Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hunan Nucien Pharmaceutical Co ROCE % Chart

Hunan Nucien Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.69 -3.65 -0.45 -34.35 -16.16

Hunan Nucien Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.11 -16.69 -15.30 -29.09 -8.52
SHSE:688189
52GF Score
Hunan Nucien Pharmaceutical Co Ltd SHSE:688189
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hunan Nucien Pharmaceutical Co ROCE % Calculation

Hunan Nucien Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-129.17/( ( (1222.438 - 339.853) + (809.472 - 93.521) )/ 2 )
=-129.17/( (882.585+715.951)/ 2 )
=-129.17/799.268
=-16.16 %

Hunan Nucien Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-60.252/( ( (809.472 - 93.521) + (786.702 - 88.787) )/ 2 )
=-60.252/( ( 715.951 + 697.915 )/ 2 )
=-60.252/706.933
=-8.52 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -8.52% mean?
Hunan Nucien Pharmaceutical Co (SHSE:688189) has a ROCE % of -8.52% as of Mar. 2026.
Is Hunan Nucien Pharmaceutical Co's ROCE % too high?
Hunan Nucien Pharmaceutical Co's current ROCE % is -8.52%. Overall, Hunan Nucien Pharmaceutical Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Nucien Pharmaceutical Co's ROCE % compare to ZTS and UTHR?
Hunan Nucien Pharmaceutical Co's ROCE % of -8.52% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Nucien Pharmaceutical Co's current ROCE % is -8.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Nucien Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co (SHSE:688189) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥2.38, compared to a current price of ¥5.98 — trading 151.3% above its estimated fair value. The current ROCE % is -8.52%. Hunan Nucien Pharmaceutical Co's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Hunan Nucien Pharmaceutical Co (SHSE:688189), the current ROCE % is -8.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hunan Nucien Pharmaceutical Co (SHSE:688189) Overvalued in 2026?

Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.98 is trading 151.3% above its estimated GF Value™ of ¥2.38. GuruFocus considers Hunan Nucien Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:688189:

  • ROCE %: -8.52%
  • GF Value™: ¥2.38 vs. price of ¥5.98 (151.3% above fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hunan Nucien Pharmaceutical Co Business Description

Address No. 1 Kangli Road, Liuyang Economic and Technological Development Zone, Hunan Province, Changsha, CHN, 510100
Hunan Nucien Pharmaceutical Co Ltd is a pharmaceutical company integrating drug research and development, production and sales. The company focuses on anti-infection, cardio-cerebral vascular, anti-tumor and other pharmaceutical fields. The company's business scope includes the manufacturing and sales of chemical pharmaceutical preparations, chemical pharmaceutical raw materials, biological drugs, chemical reagents, and auxiliaries.
52GF Score

Get the complete analysis for SHSE:688189

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.98
Price
¥2.38
GF Value